Erythropoietin (EPO) is a hypoxia-induced hormone produced in the kidneys that stimulates
hematopoiesis in the bone marrow. However, recent studies have also shown important …

The cytokine erythropoietin (EPO) protects the heart from ischemic injury, in part by
preventing apoptosis. However, EPO administration can also raise the hemoglobin …

Erythropoietin (EPO) is a 30.4-kDa glycoprotein essential for red blood cell production. In
adults, EPO is produced primarily in the kidney via an oxygen-sensing mechanism and …

Erythropoietin (EPO), originally identified for its critical hormonal role in promoting
erythrocyte survival and differentiation, is a member of the large and diverse cytokine …

Erythropoietin (EPO) is a hormone known to stimulate hematopoiesis. However, recent
research suggests additional properties of EPO, such as protection against …

Erythropoietin (Epo) was once thought to act exclusively in the formation of red blood cells.
As recently reviewed by Smith et al.[Cardiovasc. Res. 59 (2003) 538–548], Epo can also act …

Erythropoietin (Epo) has been thought to act exclusively on erythroid progenitor cells. The
identification of Epo receptor (EpoR) in non-haematopoietic cells and tissues including …

BACKGROUND: Preclinical studies have consistently shown that erythropoietin (EPO),
administered after an acute myocardial infarction (AMI), reduces infarct size and improves …

The well-established physiological function of erythropoietin (EPO) is the induction of
erythropoiesis. A growing body of evidence indicates that EPO has tissue-protective effects …

Increasing evidence indicates that high levels of serum erythropoietin (Epo) can lessen
ischemia–reperfusion injury in the heart and multiple cardiac cell types have been …